Staff ScientistExpanded recognized expertise within stability and shelf-life testing. Organized, hosted and presented in a cross-functional summit of >100 participants, including R&D, Regulatory Affairs, Operations, and Quality, on topics of stability and the future of shelf-life testing.Reagent lead for development team on a new sequencing platform from pre-concept through concept phase exit. Design, early development, evaluation, and down-selection of several new reagent technologies including next generation stability technologies with the general goals of simplifying the reagent set and improving the stabilityTotal team of 7 (Sr Sci to RA 1), with 4 direct reportsMoved to clinical team to work on the development of a distributable E2E automated IVD oncology assay. Responsible for several aspects including the design, development and external vendor coordination for in-kit control materials, contrived samples for analytical studies, novel qPCR sample quantitation methods, and drafting FDA pre-submission statements and feedback responses related to these areasSenior ScientistRecognized expert in and troubleshooting of complex Illumina workflows, chemistries, and interactions (with instruments, flowcells, bioinformatics)Lead several investigations for NovaSeq6000, including the characterization of issue index hoppingLead the iSeq100 reagent QC subteam, transitioned to reagents leadConcurrently reagents lead for MiniSeq Rapid kit launch during height of pandemic, 4 months from concept to launchParticipated in strategy teams for 10-year roadmaps for clustering technologies and in reagent stabilityDirect management of 4Scientist 2Reagents team lead on project core team to develop technology extensions to enable Genomics England 100k genomes project. Several technologies later included in the design of NovaSeq6000Direct management of 2Scientist 1Characterized and developed recombinase based isothermal amplification for v1 and v2 biochemistry for HiSeqX

Characterizing the microRNA regulatory networks in differentiating human embryonic stem cells. Analysis of miRNA expression using miRNAseq of embryonic stems cells to definitive endoderm, an early differentiation step on the path to pancreatic beta cells (insulin producing cells).Developed and wrote bioinformatic pipeline to analyze the miRNAseq analysis, providing evidence of multiple overlapping miRNAs expressed from the same hairpins within the primary transcript and independent expression profiles.

Developed an analytical scheme to globally analyze the regulatory network of the conserved microRNA let-7, moving from higher-throughput to lower-throughput methods. Coordinated with a bioinformatics collaborator on the microarray analysis. Candidates tested by RNA interference for suppression of let-7 mutants. High priority suppressors validated as direct targets by reporter gene analysis using biolistic introduction.Other projects:Initiated a project combining Immuno-precipitation and Solexa sequencing to find all of the microRNA target binding sites in C. elegans.Written and modified PERL scripts for various genomic analyses, including PCR primer mispriming analysis, BLAST parsing, and simple sequence repeat analysis.

Took over and organized an ongoing positional cloning project in zebrafish. Ordered genomic clones creating the biggest contig of the zebrafish genome at the time. Contributed this data to the beginning zebrafish genome sequencing project. Used both plate sequencing and later capillary sequencing machines to generate new markers for further genetic and physical mapping.